Emergence of Chloride as an Overlooked Cardiorenal Connector in Heart Failure

Amir Kazory a  Claudio Ronco b, c

a Division of Nephrology, Hypertension, and Renal Transplantation, University of Florida, Gainesville, FL, USA;
b Department of Nephrology, San Bortolo Hospital and International Renal Research Institute of Vicenza (IRRIV), Vicenza, Italy; c Department of Medicine, University of Padova, Padova, Italy

Keywords
Sodium · Chloride · Cardiorenal · Heart failure · Congestion · Hypochloremia

Abstract
Several studies have recently challenged the sodium-centric view that has been dominating the field of heart failure (HF) and cardiorenal syndrome. The previously observed benefits of severe dietary restriction of salt do not seem to be consistently reproduced by contemporary studies. Moreover, there is evidence that too low intake may paradoxically lead to adverse outcomes in more advanced stages of HF. Facing the escalating controversy, investigators have shifted their focus from sodium to its often overlooked counter ion in salt, the chloride. Emerging data suggest that serum chloride levels could portend robust independent prognostic value in a wide range of HF syndromes possibly stronger than that of sodium. The untoward impact of hypochloremia on the outcomes could be mechanistically linked to renal tubular regulatory pathways, neurohormonal activation, and diuretic resistance. As such, it can be a potential target of therapy in this setting. In this article, the authors provide a brief overview of the role of serum chloride as a cardiorenal connector and explore the context in which the contemporary data should be interpreted. Implementation of predictive and therapeutic strategies incorporating the emerging evidence would be refined through discussion of nuances of such findings as well as their biological and clinical relevance.

Sodium, the primary constituent of fluid homeostasis and the key determinant of extracellular volume, has been the focus of numerous investigations in the field of heart failure (HF). Over the last decades, a core principal in management of HF has been dietary modifications focusing on lower salt intake. However, more recent evidence has challenged the conventional sodium-centric view suggesting that higher salt intake may be without untoward consequences, and too low intake may paradoxically lead to adverse outcomes [1]. Some investigators have even used hypertonic saline solution to successfully treat acute HF [2]. Facing the escalating controversy, there have been calls for "a retreat from an unbridled and potentially harmful insistence on rigorous sodium restriction in those with symptomatic HF" [3]. This notion is perplexing and difficult to explain from a pathophysiologic perspective because of the known negative impact of increase in total body sodium on renal, cardiac, and vascular homeostasis. It is within this context that some investigators have shifted their focus from sodium to its often overlooked counter
ion in salt, the chloride. The question is whether the un-
anticipated adverse consequences of severe salt restriction in HF could indeed be related to lower intake of this seem-
ingly passive partner of sodium. As such, a whole host of recent studies have explored the prognostic value of serum chloride levels in the setting of HF [4–9]. In 2015, Grodin et al. [4] reported that serum chloride level on admission is a robust and independent predictor of mortality in acute HF, and it may even have a stronger prognostic value than sodium. Comparable results were later reported in stable chronic HF, where lower serum chloride was indepen-
dently and incrementally associated with an increased risk of death [5–7]. Similar to acute HF, the prognostic value of serum sodium was markedly diminished when chloride levels were entered into the models, suggesting a stronger role for chloride. These findings were confirmed for HF patients both with or without reduced ejection fraction [8, 9]. The 2 common themes in all these studies are (1) hy-
pochloremia is an independent predictor of adverse out-
comes in a wide range of HF syndromes and (2) its asso-
ciation with mortality seems to be stronger than that of hyponatremia.

The underlying mechanisms for these interesting and somewhat unexpected findings are not completely un-
derstood. Chloride has unique homeostatic roles that are distinct from sodium. It is the main modulator of renin secretion and tubuloglomerular feedback in the kidney and is the key regulator of sodium transport pathways in the loop of Henle and distal convoluted tubule. Hypo-
chloremia triggers renin secretion and increases the activ-
ity of sodium-potassium-chloride cotransporter in the thick ascending limb of loop of Henle as well as thiazide-
sensitive sodium-chloride symporter in the distal tubule. As such, it could be hypothesized that low serum chloride level (as a surrogate for depleted total body chloride stores due to chronic use of diuretics) would interfere with reg-
ulatory mechanisms that facilitate renal excretory func-
tions. Clinical data, albeit limited, support this patho-
physiologic notion; hypochloremia is clearly linked to neurohormonal activation and diuretic resistance, lead-
ing to impaired decongestion in patients with HF [10, 11].

If these relationships are causal, and chloride is not a mere marker but a mechanistically relevant pathogenic cardiorenal connector, it could represent a potential tar-
get of therapy in HF. Sodium-independent correction of hypochloremia would then be expected to portend a mul-
titude of benefits such as increase in urinary sodium ex-
cretion, reduction in neurohormonal activation, and im-
proved survival. The idea of supplementing chloride and exploring the outcomes is not novel. Several decades ago, the investigators tried to use sodium-free chloride sup-
plementation to treat refractory fluid retention, although that line of research was not followed, in part due to wide availability of more efficient and safer diuretics [12, 13]. More recently, a proof of concept study was undertaken to explore neurohormonal and cardiorenal effect of lysine chloride supplementation in 10 patients with stable HF and chronic use of diuretics [10]. The results were not consistently positive; while there were signals of efficient decongestion (e.g., hemoconcentration and weight loss), the investigators noted a paradoxical rise in plasma renin activity and did not observe any improvement in diuretic response. Pharmacological increase in serum chloride levels using acetazolamide is yet another way to explore this relationship. Acetazolamide increases serum chlor-
ide levels, independent of sodium, through inhibition of intracellular and luminal carbonic anhydrase in the prox-
imal tubules. In the recently published Diamox to In-
crease the Urinary Excretion of Sodium: an Investigational-
Study in Congestive Heart Failure (DIURESIS-CHF) trial, patients with acute HF that were randomized to re-
ceive acetazolamide in addition to lower doses of loop diuretics experienced urinary sodium excretion and de-
congestion similar to those who received high dose loop diuretics alone (i.e., an increase in “loop diuretic effica-
cy”) [14]. Acetazolamide in Decompensated HF with Volume Overload trial is designed to examine the impact of acetazolamide on decongestion when added to high-
dose loop diuretics in patients with acute HF [15].

So, what can we do with the data generated by this se-
ries of overall well-done studies, and how can their find-
ings improve our understanding and inform our clinical practice?

First, we need to be cognizant that the majority of these data are coming either from retrospective studies or from unplanned post hoc data analysis of trials in which the changes in the level of serum chloride were not the original question nor the primary or secondary endpoint. Therefore, while highly consistent, they are fraught with inherent limitations of such analyses. They should be re-
garded as hypothesis-generating evidence, which needs to be further tested in large prospective trials with serial measurements of serum chloride.

Second, chloride is also involved in acid-based homeo-
stasis and is tightly linked to changes in PH. Therefore, future studies need to determine whether changes in PH could modulate the association of hypochloremia and clinical outcomes.

Third, in view of these findings, HF therapy trials need to examine the impact of their interventions on serum
chloride levels and include it as a safety endpoint. Indeed, there should be a demand for reporting of the changes in chloride in such studies. Similarly, the contemporary risk prediction models of HF can be revisited to determine whether incorporation of serum chloride level would add to their predictive value.

Finally, despite biological plausibility and existing clinical suspicion of a pathogenic role for hypochloremia in the setting of HF, the findings of very few available interventional trials have so far not been overwhelmingly convincing. For the time being, serum chloride seems to identify a subset of HF patients with more advanced cardio-renal impairment who present with higher diuretic requirement and heavier comorbid burden.

Disclosure Statement

The authors have no conflict of interest regarding the content of this manuscript.

Funding Sources

No specific financial support was obtained for preparation of this article.

Author Contributions

Dr. Amir Kazory wrote the draft of the manuscript and Professor Ronco provided critical revision.

References